Presentation on theme: "THE COMPLEMENT SYSTEM. The complement system is a set of plasma proteins that act in a cascade to attack and kill extracellular pathogens. Approximately."— Presentation transcript:
The complement system is a set of plasma proteins that act in a cascade to attack and kill extracellular pathogens. Approximately 30 components: –activating molecules –regulator factors –complement receptors –membrane proteins wich inhibit the lysis of host cells Most of the complement proteins and glycoproteins are produced in the liver in an inactive form (zymogen). Activation is induced by proteolitic cleavage.
AMPLIFICATION OF THE COMPLEMENT CASCADE inactive precursors limited proteolysis activating surface enzyme Activating surface needed!
ACTIVATION OF THE COMPLEMENT SYSTEM COMPLEMENT SYSTEM CLASSICAL PATHWAY MB-LECTIN PATHWAY ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION RECRUITMENT OF INFLAMMATORY CELLS OPSONIZATION OF PATHOGENS DIRECT KILLING OF PATHOGENS FACILITATING PHAGOCYTOSIS
C1 is always present in serum but it can operate on an activating surface in normal case Low affinity binding to the Fc region of antibody conformational change activation Multiple interaction with immune complexes Collagen „legs” Gobular „heads” THE C1 COMPLEX
Regulatory proteins on human cells protect them from complement-mediated attack
CD59 prevents assembly of terminal complement components into a membrane pore
DAF C1Inh Properdin positive feedback Factor I CR1MCP C4bp Factor I F act -H CR1MCP DAF CD59 HRF S-protein -2macrogl LECTIN PATHWAY Regulation of complement system membrane protein soluble molecule C-pept.ase N
C1Inh: C1-inhibitor (serine-protease inhibitor) Factor I: inhibits both C3 convertases in the presence of co-factors (C4bp – classical pw., factor H – alternative pw., MCP – both) DAF(CD55): Decay Accelerating Factor MCP: Membrane Cofactor Protein MIRL(CD59): Membrane Inhibitor of Reactive Lysis Properdin: stabilize convertases of alternative pathway MAJOR REGULATING FACTORS OF COMPLEMENT SYSTEM
Deficiencies of complement system – cascade molecules Not the lysis of cells is the most important function of the complement system
Deficiencies of regulatory molecules, receptors
One of the major function of C1 INHIBITOR C1q binds to IgM on bacterial surface C1q binds to at least two IgG molecules on bacterial surface Binding of C1q to Ig activates C1r, which cleaves and activates the serine protease C1s C1INH dissociates C1r and C1s from the active C1 complex
HEREDITARY ANGIONEUROTIC EDEMA (HANE) (HEREDITARY C1INH DEFECT) 17-year old boy - severe abdominal pain (frequent sharp spasms, vomiting) appendectomia normal appendix similar symptoms occured repeatedly earlier in his life with watery diarrhea family history of prior illness immunologist’s suspicion: hereditary angioneurotic edema level of C1INH: 16% of the normal mean daily doses of Winstrol (steroid) – marked diminution in the frequency and severity of symptoms intravenous purified C1INH became avaible by the time Main symptoms: swellings of skin, guts, respiratory tracts serious acute abdominal pain, vomiting larynx swelling – suffocation, may cause death Treatment: iv C1INH, FFP, steroid kallikrein and bradykinin receptor antagonists Child with symptoms of HANE
Pathogenesis of hereditary angioneurotic edema bradykinin and C2-kinin: enhance the permeability of postcapillar venules by contraction of endothel holes in the venule walls edema formation C1 is always active without activating surface because plasmine is always active Inhibition by C1INH in many steps activation of XII factor activation of kallikrein activation of proactivator cleveage of kininogen to generate bradykinin, vasoactive peptide activation of C1 cleveage of plasminogen to generate plasmin cleveage of C2 to generate C2a cleveage of C2a to generate C2-kinin, vasoactive peptide
Q&AHANE 1. Activation of complement system results in the release of histamine and chemokines, which normally produce pain, heat and itching. Why is the edema fluid in HANE free of cellular components, and why does the swelling not itch? Histamine release on complement activation and recruiting of leukocytes is caused by C3a and C5a, both generated by the C3/C5 convertases. In HANE C1 constantly activate C2 and C4 in the plasma but C4b is rapidly inactivated because it does not bind to activating surface; for that reason, and because the concentrations of C2 and C4 are relatively low, no C3/C5 convertase is formed. Edema is caused by C2-kinin and bradykinin. 2. Which complement component levels will be decreased? Why? C2 and C4, because of the continous cleavage by activated C1.
4. What about the levels of the terminal components? Q&AHANE 3. Would you expect the alternative pathway components to be low, normal or elevated? C1 plays no part in the alternative pathway. This pathway is not affected. The unregulated activation of the early components does not lead to the formation of the C3/C5 convertase, so the terminal components are not abnormally activated. 5. Despite the complement deficiency in patients with HANE, they are not unduly susceptible to infection. Why not? The alternative pathway of complement activation is intact and these are compensated for by the potent amplification step from the alternative pathway. 6. How might you decide the background of the laryngeal edema (HANO or anaphylactic reaction)? If the laryngeal edema is anaphylactic, it will respond to epinephrine. If it is due to HANO, it will not, C1INH needed.
Acquired clonal mutation of PIG-A gene in myeloid progenitors – no GPI- enchored proteins in the cell membrane of affected cells (rbc, plt, wbc) CD59 and CD55 complement regulatory proteins are GPI-enchored proteins No CD59 and/or CD55 PNH patients are highly susceptible to complement-mediated lysis The lysis of red blood cells leads to high levels of hemoglobins in the blood that appears in the urine (hemoglobinuria) Elevated levels of TF derived from complement-damaged leukocytes cause thromboses PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Change in the colour of urine samples taken from PNH patient during the day
Paroxysmal nocturnal hemoglobinuria (PNH) symptoms and therapy Haemolytic anaemia and associated symptoms Haemoglobin and its products in the urine Thrombosis: in brain veins, mesentheric veins, vv. hepaticae (Budd-Chiari- syndrome) Transformation to acut myelogenous leukemia (AML), aplastic anaemia, myelodisplastic syndrome (MDS) Specific th.: eculizumab (Soliris - anti-C5 monoclonal antibody) Curative th.: bone marrow transplantation Alternative th.: steroids (general immunosuppression) Anticoagulants: sc. heparin p.o. kumarin Iron replacement Transfusion (filtered-irradiated blood)
C1Inh: inhibitor of C1 and MBL (serin protease inhibitor – multiple effects) α2-macroglobulin: inhibitor of MBL C4bp: C4 binding protein - inhibitor of the classical C3 convertase Factor H: inhibitor of the alternative C3 convertase Factor I: cleaves C4b and C3b Properdin: stabilizes the convertases of the alternative pathway DAF (CD55): Decay Accelerating Factor (of C3 convertases) MCP (CD46): Membrane Cofactor Protein, cleavage of C3 convertases with factor I CR1: complement receptor 1, inhibitor of C3 convertases CD59 (MIRL): Membrane Inhibitor of Reactive Lysis – inhibits binding of C9 to C8 HRF: Homologous Restriction Factor (inhibits binding of C8 and C9) Abbreviations